Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Nephrectomized, metastatic Clear Cell RCC patients not suitable for cytokines or anti-angiogenesis (bevacizumab or sunitinib) therapy as first line treatment~2. Age ≥ 65years~3. ECOG Performance Status of ≤ 2~4. MSKCC prognostic score, good or intermediate~5. Life expectancy of at least 12 weeks.~6. Subjects with at least one uni-dimensional (for RECIST) measurable lesion. Lesions must be measured by CT/MRI-scan.~7. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of therapy:~   * Hemoglobin \> 9.0 g/dl~  * Absolute neutrophil count (ANC) ≥ 1,500/mm3~  * Platelet count ≥ 100,000/μl~  * Total bilirubin ≤ 1.5 times the upper limit of normal~  * ALT and AST ≤ 2.5 x upper limit of normal (≤ 5 x upper limit of normal for patients with liver involvement of their cancer)~  * Alkaline phosphatase ≤ 4 x upper limit of normal~  * PT-INR/PT ≤ 1.5 x upper limit of normal \[Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.\]~  * Serum creatinine ≤ 1.5 x upper limit of normal.~8. Ability to take correctly oral drugs.~9. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.~10. Written Informed Consent~11. To be able to understand medical instruction and to fill in the patient's diary. If not, check if adequately supported by his/her family.~Exclusion Criteria:~1. Previous first line treatment for mRCC. No adjuvant or neoadjuvant treatments are allowed.~2. Symptomatic metastatic brain or meningeal tumors (unless the patient is \> 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry)~3. History of cardiac disease: congestive heart failure \>NYHA class 2; active CAD (MI more than 6 months prior to study entry is allowed); cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension.~4. History of previous or present seizure disorder requiring medication (such as steroids or anti-epileptics), organ allograft, HIV infection or chronic hepatitis B or C~5. Active clinically serious infections (≥ grade 2 NCI-CTC version 3.0)~6. Patients undergoing renal dialysis~7. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors \[Ta, Tis \& T1\] or any cancer curatively treated \> 3 years prior to study entry.~8. Patients with evidence or history of bleeding diathesis~9. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results~10. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study~11. Known allergy to sorafenib or one of its constituents

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib (Type: EXPERIMENTAL): Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to protocol.~In case of disease progression Sorafenib administration will be discontinued.

Based on this trial design, predict the completion outcome and termination type (if applicable).